ReviewChinese clinical oncology2015
The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer.
Review in Chinese clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04129216 (The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer), which is not on this map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers.Frontiers in oncology · 2022Pooled it
- Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial.Journal of cancer research and clinical oncology · 2023Trial
- Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031).Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Research-based PAM50 signature and long-term breast cancer survival.Breast cancer research and treatment · 2020Trial
- Trial
- Axillary Management after Neoadjuvant Endocrine Therapy (NET).Annals of surgical oncology · 2026Article
- Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response.Translational oncology · 2025Article
- Efficacy of Presurgical Short-Term Endocrine Therapy During the Waiting Period for Surgery in Postmenopausal Hormone Receptor-Positive Breast Cancer.The breast journal · 2025Article
- Clinical efficacy of combined goserelin and anastrozole in neoadjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer.Discover oncology · 2024Article
- Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer.Current treatment options in oncology · 2024Review
- A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer.Breast cancer research : BCR · 2024Article
- Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers.Nature communications · 2023Article
- Neoadjuvant systemic therapy for breast cancer.The British journal of surgery · 2023Article
- Fall in Ki67 Index After Short-Term Preoperative Letrozole: a Gateway to Assess the Response in Hormone-Positive Early Breast Cancers.Indian journal of surgical oncology · 2023Article
- Ki 67: a Promising Prognostic Marker in Early Breast Cancer-a Review Article.Indian journal of surgical oncology · 2023Review
- Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy.Therapeutic advances in medical oncology · 2023Review
- Systemic therapy for early-stage breast cancer: learning from the past to build the future.Nature reviews. Clinical oncology · 2022Review
- Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study.Breast cancer research and treatment · 2022Article
- Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.Breast cancer research : BCR · 2022Article
- The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy.Breast cancer research and treatment · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
The Alliance for Clinical Trials in Oncology cooperative group has designed a phase III neoadjuvant clinical trial (ALTERNATE trial) which randomizes women with cT2-4 N0-3 M0 ER+/Her2- invasive breast cancer to either anastrozole, fulvestrant or its combination to assess a biomarker-driven treatment strategy to identify women with a low risk of disease recurrence. This strategy incorporates the findings that: higher expression of the proliferation marker, Ki67, after 2 weeks of neoadjuvant endocrine therapy (ET), is associated with poor recurrence-free survival, and that patients with surgical findings of pT1/2, pN0 disease, Ki67 ≤2.7% and ER Allred score of 3-8 after neoadjuvant ET have extremely low recurrence rates. We present a description and rationale for the design of this trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.